---
title: Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)
nct_id: NCT00862342
overall_status: COMPLETED
phase: PHASE2
sponsor: Asan Medical Center
study_type: INTERVENTIONAL
primary_condition: Metastatic Colorectal Cancer
countries: South Korea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00862342.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00862342"
ct_last_update_post_date: 2012-07-17
last_seen_at: "2026-05-12T06:17:34.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)

**Official Title:** Efficacy and Safety of Second-line Combination Chemotherapy With Avastin in Patients With Metastatic Colorectal Cancer Who Have Received First-line Chemotherapy Plus Avastin

**NCT ID:** [NCT00862342](https://clinicaltrials.gov/study/NCT00862342)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 78
- **Lead Sponsor:** Asan Medical Center
- **Conditions:** Metastatic Colorectal Cancer
- **Start Date:** 2009-01
- **Completion Date:** 2012-06
- **CT.gov Last Update:** 2012-07-17

## Brief Summary

Bevacizumab beyond progression has been proven to be safe in the community setting (BRiTE) and in the post-marketing study (BEAT), and confirmed its efficacy and safety in the first line with all regimens of chemotherapy. A total of 1,953 patients were treated in BRiTE. At median follow-up of 17.5 mo, there were 1,369 1st PD and 839 deaths. Among patients with 1st PD, 65.2% received any 2nd-line chemotherapy, 34.8% received cetuximab, and 53.8% received BBP. In a multivariate analysis, Bevacizumab beyond first progression and exposure to any 2nd-line chemotherapy were independently associated with increased overall survival (both p \< 0.0001). Bevacizumab beyond progression appears to be associated with longer overall in BRiTE.

The investigators planned a prospective study to prove this phenomenon of bevacizumab beyond progression.

## Detailed Description

Patients should have been treated with bevacizumab plus chemotherapy as a 1st line treatment, and after 1st progression, these patients will be accrued in this study of bevacizumab plus chemotherapy as a 2nd line treatment, and the combined chemotherapy will be chosen by physician's decision in consider with previous chemotherapy.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Histologically documented colorectal adenocarcinoma
* Progression during first-line bevacizumab containing chemotherapy within 3 months
* No serious toxicity to bevacizumab of 1st line treatment
* Unresectable metastases
* Uni-dimensional measurable lesion(s) by RECIST
* Age over 18 years old
* ECOG 0-2
* Adequate organ functions by clinical laboratory exams

Exclusion Criteria:

* Other tumor type than adenocarcinoma
* CNS metastases
* GI bleeding
* Hypersensitivity to any of chemotherapeutic agents
* Prior use of cetuximab or other targeted agents other than bevacizumab
* Major surgery within 6 weeks
* Other serious illness
```

## Arms

- **Bevacizumab** (EXPERIMENTAL) — Bevacizumab continuation plus chemotherapy in patients who have failed previous bevacizumab plus other chemotherapy

## Interventions

- **Bevacizumab (Avastin)** (DRUG) — Bevacizumab plus chemotherapy (chemotherapy will be chosen by physician's decision)

## Primary Outcomes

- **Progression free survival** _(time frame: 6 weeks)_

## Secondary Outcomes

- **Overall survival** _(time frame: 6 weeks)_
- **Toxicity profiles** _(time frame: 2 or 3 weeks)_

## Locations (1)

- Asan Medical Center, Seoul, Songpa-gu, South Korea

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.asan medical center|seoul|songpa-gu|south korea` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00862342.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00862342*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*